Experimental RSV vaccine prompts antibody surge
by Press Release from Outbreak News Today on (#4MH7D)
A novel experimental vaccine against respiratory syncytial virus (RSV), a leading cause of severe respiratory illness in the very young and the old, has shown early promise in a Phase 1 clinical trial. The candidate, DS-Cav1, was engineered and developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the ["]
The post Experimental RSV vaccine prompts antibody surge appeared first on Outbreak News Today.